136 related articles for article (PubMed ID: 28919005)
1. Ex vivo γH2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity.
De-Colle C; Yaromina A; Hennenlotter J; Thames H; Mueller AC; Neumann T; Stenzl A; Scharpf M; Fend F; Ricardi U; Baumann M; Zips D; Menegakis A
Radiother Oncol; 2017 Sep; 124(3):386-394. PubMed ID: 28919005
[TBL] [Abstract][Full Text] [Related]
2. γH2AX assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material.
Menegakis A; von Neubeck C; Yaromina A; Thames H; Hering S; Hennenlotter J; Scharpf M; Noell S; Krause M; Zips D; Baumann M
Radiother Oncol; 2015 Sep; 116(3):473-9. PubMed ID: 25866027
[TBL] [Abstract][Full Text] [Related]
3. Residual γH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness.
Menegakis A; De Colle C; Yaromina A; Hennenlotter J; Stenzl A; Scharpf M; Fend F; Noell S; Tatagiba M; Brucker S; Wallwiener D; Boeke S; Ricardi U; Baumann M; Zips D
Radiother Oncol; 2015 Sep; 116(3):480-5. PubMed ID: 26297183
[TBL] [Abstract][Full Text] [Related]
4. Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
Meneceur S; Löck S; Gudziol V; Hering S; Bütof R; Rehm M; Baumann M; Krause M; von Neubeck C
Radiother Oncol; 2019 Aug; 137():24-31. PubMed ID: 31048234
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo γH2AX assay for tumor radiosensitivity in primary prostate cancer patients and correlation with clinical parameters.
Marinescu IM; Rogg M; Spohn S; von Büren M; Kamps M; Jilg CA; Fountzila E; Papadopoulou K; Ceci L; Bettermann A; Ruf J; Benndorf M; Adebahr S; Zips D; Grosu AL; Schell C; Zamboglou C
Radiat Oncol; 2022 Oct; 17(1):163. PubMed ID: 36199143
[TBL] [Abstract][Full Text] [Related]
6. Tumor heterogeneity determined with a γH2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models.
Rassamegevanon T; Löck S; Range U; Krause M; Baumann M; von Neubeck C
Radiother Oncol; 2017 Sep; 124(3):379-385. PubMed ID: 28739384
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of γH2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors.
Rassamegevanon T; Löck S; Baumann M; Krause M; von Neubeck C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30181446
[TBL] [Abstract][Full Text] [Related]
8. Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual γH2AX.
Rassamegevanon T; Löck S; Baumann M; Krause M; von Neubeck C
Radiother Oncol; 2019 Oct; 139():94-100. PubMed ID: 31445839
[TBL] [Abstract][Full Text] [Related]
9. γH2AX foci assay in glioblastoma: Surgical specimen versus corresponding stem cell culture.
Riedel A; Klumpp L; Menegakis A; De-Colle C; Huber SM; Schittenhelm J; Neumann M; Noell S; Tatagiba M; Zips D
Radiother Oncol; 2021 Jun; 159():119-125. PubMed ID: 33775712
[TBL] [Abstract][Full Text] [Related]
10. Induction and rejoining of DNA double-strand breaks in the lymphocytes of prostate cancer patients after radium-223 treatment as assessed by the γH2AX foci assay.
Runge R; Oehme L; Grosche-Schlee S; Braune A; Freudenberg R; Kotzerke J
Nuklearmedizin; 2019 Sep; 58(5):387-394. PubMed ID: 31387125
[TBL] [Abstract][Full Text] [Related]
11. Intra-patient and inter-patient comparisons of DNA damage response biomarkers in Nasopharynx Cancer (NPC): analysis of NCC0901 randomised controlled trial of induction chemotherapy in locally advanced NPC.
Chua KLM; Yeo ELL; Shihabudeen WA; Tan SH; Shwe TT; Ong EHW; Lam PYP; Soo KC; Soong YL; Fong KW; Tan TWK; Wee JTS; Chua MLK
BMC Cancer; 2018 Nov; 18(1):1095. PubMed ID: 30419858
[TBL] [Abstract][Full Text] [Related]
12. Endogenous and radiation-induced expression of gammaH2AX in biopsies from patients treated for carcinoma of the uterine cervix.
Olive PL; Banuelos CA; Durand RE; Kim JY; Aquino-Parsons C
Radiother Oncol; 2010 Jan; 94(1):82-9. PubMed ID: 19903578
[TBL] [Abstract][Full Text] [Related]
13. Survival Fraction at 2 Gy and γH2AX Expression Kinetics in Peripheral Blood Lymphocytes From Cancer Patients: Relationship With Acute Radiation-Induced Toxicities.
Pouliliou SE; Lialiaris TS; Dimitriou T; Giatromanolaki A; Papazoglou D; Pappa A; Pistevou K; Kalamida D; Koukourakis MI
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):667-74. PubMed ID: 25892583
[TBL] [Abstract][Full Text] [Related]
14. Low-dose hypersensitive gammaH2AX response and infrequent apoptosis in epidermis from radiotherapy patients.
Simonsson M; Qvarnström F; Nyman J; Johansson KA; Garmo H; Turesson I
Radiother Oncol; 2008 Sep; 88(3):388-97. PubMed ID: 18524402
[TBL] [Abstract][Full Text] [Related]
15. Residual gammaH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy.
Olive PL; Banáth JP; Keyes M
Radiother Oncol; 2008 Mar; 86(3):336-46. PubMed ID: 17904670
[TBL] [Abstract][Full Text] [Related]
16. The potential value of the neutral comet assay and γH2AX foci assay in assessing the radiosensitivity of carbon beam in human tumor cell lines.
Zhao J; Guo Z; Zhang H; Wang Z; Song L; Ma J; Pei S; Wang C
Radiol Oncol; 2013; 47(3):247-57. PubMed ID: 24133390
[TBL] [Abstract][Full Text] [Related]
17. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life.
Osman SO; Horn S; Brady D; McMahon SJ; Yoosuf AB; Mitchell D; Crowther K; Lyons CA; Hounsell AR; Prise KM; McGarry CK; Jain S; O'Sullivan JM
Radiat Oncol; 2017 Mar; 12(1):53. PubMed ID: 28288658
[TBL] [Abstract][Full Text] [Related]
19. DNA repair foci and late apoptosis/necrosis in peripheral blood lymphocytes of breast cancer patients undergoing radiotherapy.
Marková E; Somsedíková A; Vasilyev S; Pobijaková M; Lacková A; Lukačko P; Belyaev I
Int J Radiat Biol; 2015; 91(12):934-45. PubMed ID: 26537244
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Hypersensitive Response for Residual pATM and γH2AX Foci in Normal Fibroblasts of Cancer Patients.
Słonina D; Kowalczyk A; Janecka-Widła A; Kabat D; Szatkowski W; Biesaga B
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):756-766. PubMed ID: 29248168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
